leuprorelin acetate

Poland

Drugs containing this active substance

  • ELIGARD 22.5 MG

    The medicinal product is used in adult men for the treatment of metastatic prostate cancer (hormone-sensitive) and for the treatment of high-risk non-metastatic prostate cancer (in combination with radiotherapy).

    Form: solution for injection, powder and solvent for preparation of

    Active substance Dosage
    leuprorelin acetate 22.5 mg

    ATC: L02AE02

    Manufacturer: Recordati Industria Chimica e Farmaceutica S.p.A

  • ELIGARD 45 MG

    The medicinal product is used in adult men for the treatment of metastatic prostate cancer (hormone-sensitive) and for the treatment of high-risk non-metastatic prostate cancer (in combination with radiotherapy).

    Form: solution for injection, powder and solvent for preparation of

    Active substance Dosage
    leuprorelin acetate 45 mg

    ATC: L02AE02

    Manufacturer: Recordati Industria Chimica e Farmaceutica S.p.A

  • ELIGARD 7.5 MG

    The medicinal product is used in adult men for the treatment of metastatic prostate cancer (hormone-sensitive) and for the treatment of high-risk non-metastatic prostate cancer (in combination with radiotherapy). It works by inhibiting the production of testosterone.

    Form: solution for injection, powder and solvent for preparation of solution for subcutaneous injection

    Active substance Dosage
    leuprorelin acetate 7.5 mg

    ATC: L02AE02

    Manufacturer: Recordati Industria Chimica e Farmaceutica S.p.A

  • LEUPROSTIN

    It is used for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and for the treatment of locally advanced or limited prostate cancer during or after radiotherapy.

    Form: implant

    Active substance Dosage
    leuprorelin acetate 3.6 mg

    ATC: L02AE02

    Manufacturer: EVER Pharma Jena GmbH

  • LEUPROSTIN

    The medicine is used for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and for the treatment of locally advanced or limited prostate cancer during or after radiotherapy.

    Form: implant

    Active substance Dosage
    leuprorelin acetate 5 mg

    ATC: L02AE02

    Manufacturer: EVER Pharma Jena GmbH

  • LIBREXA

    The medicine is used in men for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and as adjuvant therapy during and after radiotherapy for locally advanced prostate cancer.

    Form: implant in ampoule-syringe

    Active substance Dosage
    leuprorelin acetate 10.72 mg
    leuprorelin 12.1 mg

    ATC: L02AE02

    Manufacturer: AMW GmbH

  • LUTRATE DEPOT

    Lutrate Depot is used in the palliative treatment of advanced prostate cancer.

    Form: powder and solvent for preparation of suspension for injection with prolonged release

    Active substance Dosage
    leuprorelin acetate 22.5 mg

    ATC: L02AE02

    Manufacturer: GP-PHARM S.A.